Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
This study has been designed to collect long-term follow-up information for patients who received REGN2810 in other clinical studies and to allow re-treatment for eligible patients.
Advanced Malignancies
DRUG: REGN2810
Overall survival, from the first dose of study drug administered in the parent REGN2810 clinical study to death or date of last censoring, up to 8 years|Safety measured by the number of patients with AEs, AEs leading to discontinuation, SAEs, drug-related AEs, Immune-related adverse events (irAEs), and death as outcome., Safety includes the number of patients with AEs, AEs leading to discontinuation, SAEs, drug-related AEs, Immune-related adverse events (irAEs), and death as outcome., up to 8 years
Response duration (time from best overall response of partial or complete response, to time to first documented disease progression), up to 8 years|Duration of disease control (time from best overall response of SD as well as PR and CR to time to first do documented disease progression), up to 8 years
This study has been designed to collect long-term follow-up information for patients who received REGN2810 in other clinical studies and to allow re-treatment for eligible patients.